Enovis Corporation
ENOVHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeEnovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. At a $1.56B market cap, Enovis Corporation ranks as a small-cap company within healthcare. It operates through two segments: Prevention and Recovery, and Reconstructive segments.
Market Cap
$1.56B
Beta
1.50
P/E (TTM)
—
P/E (Fwd)
6.64
EPS (TTM)
$-19.18
EPS (Fwd)
$4.08
ROE
-55.4%
ROA
1.1%
Cash
$33.1M
Total Debt
$1.41B
Free CF
$206.9M
52W Change
3.0%
Annual Financials
Cash vs Debt
Enovis Corporation carries $1.41B in total debt against $33.1M in cash reserves — debt is roughly 42.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $206.9M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -55.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 1.1% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $1.56B (2022) to $2.25B (2025), reflecting a 44% increase over the period.
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Enovis Corporation's trajectory.